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Abstract
Background: International guidelines and U.S. guidelines prior to 2012 only recommended testing for hepatitis C
virus (HCV) infection among patients at risk, but adherence to guidelines is poor, and the majority of those infected
remain undiagnosed. A strategy to perform one-time testing of all patients born during 1945–1965, birth cohort testing,
may diagnose HCV infection among patients whose risk remains unknown. We sought to determine if a birth-cohort
testing intervention for HCV antibody positivity helped identify patients with fewer documented risk factors or medical
indications than a pre-intervention, risk-based testing strategy.
Methods: We used a cross-sectional design with retrospective electronic medical record review to examine patients
identified with HCV antibody positivity (Ab+) during a pre-intervention (risk-based) phase, the standard of care at the
time, vs. a birth-cohort testing intervention phase. We compared demographic and clinical characteristics and HCV
risk-associated factors among patients whose HCV Ab +was identified during the pre-intervention (risk-based testing)
vs. post birth-cohort intervention phases. Study subjects were patients identified as HCV-Ab + in the baseline (risk-based)
and birth-cohort testing phases of the Hepatitis C Assessment and Testing (HepCAT) Project.
Results: Compared to the risk-based phase, patients newly diagnosed with HCV Ab + after the birth-cohort intervention
were significantly less likely to have a history of any substance abuse (30.5 % vs. 49.5 %, p = 0.02), elevated alanine
transaminase levels of > 40 U/L (22.0 % vs. 46.7 %, p = 0.002), or the composite any risk-associated factor (55.9 %
vs. 79.0 %, p = 0.002).
Conclusions: Birth-cohort testing is an useful strategy for identifying previously undiagnosed HCV Ab + because
it does not require providers ask risk-based questions, or patients to disclose risk behaviors, and appears to identify HCV
Ab + in patients who would not have been identified using a risk-based testing strategy.
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Background
An estimated 3.2 million persons are infected with the
hepatitis C virus (HCV) in the U.S [1, 2]. In the absence of
testing, care, and treatment, HCV infection is predicted to
cause 1.5 million cases of cirrhosis and contribute to
900,000 deaths over the lifetime of infected persons [3].
Curative treatment for HCV infection is available, and
early testing is associated with early entry into care [4–8].
Previous U.S. and many international guidelines recom-
mend testing patients at risk for HCV infection including
those with a history of injection drug use, recipients of
transfusions or organ transplants, and those with ele-
vated alanine aminotransferase (ALT) levels [7–12].
However, providers are often non-adherent to risk-
based testing guidelines [13], and the majority of those
infected remained undiagnosed [13–15].
Data have demonstrated that approximately 77 % of all
HCV-infected persons in the U.S. were born between
1945 and 1965 [16] and adults in this cohort have a
HCV infection prevalence of 3.2 %, approximately five
fold higher than other adults outside of this age cohort
[17]. Therefore, in the U.S. one-time testing of all pa-
tients born during 1945–1965, birth-cohort testing, is
now recommended by the Centers for Disease Control
and Prevention and the US Preventive Services Task
Force in addition to risk-based testing [18–20]. In
addition, it is possible that a birth-cohort-based testing
strategy is more effective for identification of HCV-
infected patients who have no known risk factors or
medical indications for HCV testing. To investigate this,
we examined the characteristics and risk factors of
HCV- Ab + persons who were identified during a pre-
intervention phase when risk-based testing was the
standard of care vs. after a birth-cohort testing interven-
tion. We hypothesized that patients identified as HCV-
Ab + using a birth-cohort testing strategy would be
less likely to have documented risk factors or medical in-
dications as compared to patients identified as HCV-
Ab + by traditional risk-based testing strategy.
Methods
Study setting
The study was conducted at three community-based
primary care clinics affiliated with Montefiore Medical
Center, a regional healthcare system including four
hospitals and twenty three outpatient sites, located in
the Bronx, New York. The estimated prevalence of
HCV Ab + in the population served by the study sites is
7.7 % [13].
Study design and population
Study subjects were drawn from the baseline (risk-
based testing) and birth-cohort testing phases of the
Hepatitis C Assessment and Testing Project (HepCAT),
a cross-sectional intervention study investigating a
birth cohort testing strategy for HCV Ab+, described
previously [13, 21, 22]. In short, patients were eligible to
be included in the risk-based testing group if they had a
clinic visit at one of the study sites during the baseline
phase of HepCAT (1 January 2008 to 29 February 2008).
Patients were eligible to be included in the birth-cohort
testing group if they were tested at a clinic visit during the
birth-cohort phase of HepCAT (9 March 2009–30 June
2009). The birth-cohort intervention phase was con-
ducted for four months to maximize the number of
patients who were tested for HCV. Patients were con-
sidered newly-identified HCV- Ab + and included in
this study if they had no previous record of HCV Ab+,
and tested positive for HCV antibody, at any hospital or
site in the Montefiore system, within 2 years before or
90 days after the qualifying clinic visit for the baseline
phase or within 90 days after the clinic visit date in the
birth-cohort (intervention) phase. Retrospective electronic
medical record (EMR) review was used to examine clinical
characteristics and HCV risk factors of patients identified
with HCV Ab + during the pre-intervention phase (when
risk-based testing was the standard of care), vs. after a
birth-cohort testing intervention.
Data extraction
For each research subject we extracted data from
Montefiore’s Clinical Information System including
demographic information associated with the qualify-
ing clinic visit, and clinical information dating back
to March 1997, from any contacts the subjects had
with a Montefiore hospital or outpatient site. This in-
cluded inpatient and outpatient ICD-9 diagnosis codes,
prescription and inpatient medication records, and labora-
tory testing results.
Birth-cohort vs. Risk-based testing
During the baseline (pre-intervention) phase of the par-
ent study most patients tested for HCV antibody had a
documented risk factor or medical indication suggesting
that providers were following risk-based testing recom-
mendations for HCV testing [13]. During the birth-
cohort phase, a reminder sticker was placed on each
progress note for every visit (Fig. 1). The reminder rec-
ommended that providers order an HCV antibody test
for all patients born during 1945–1964, regardless of any
other identified risk.
Markers of risk/definitions
Because we were unable to directly measure primary risks
for HCV exposure (e.g. injection drug use) we measured
factors/markers that may be indicative of being at in-
creased risk for HCV exposure and other demographic
characteristics (such as age and race/ethnicity) previously
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shown to be associated with HCV antibody positivity. A
factor/marker for testing was considered present if it ap-
peared anytime in the medical record before the index
clinic visit. Independent variables included age, sex, race/
ethnicity, any substance abuse (coded as present if an
ICD-9 code for substance abuse/dependence or a positive
urine toxicology for amphetamines, barbiturates, cocaine,
or methadone was recorded), HIV infection (ICD-9 code
or positive antibody test confirmed by western blot), sexu-
ally transmitted infection [23, 24] (ICD-9 code indicating
gonorrhea or chlamydia or positive gonorrhea or chla-
mydia PCR probe), alcohol abuse [25, 26] (ICD-9 code for
alcohol dependence or alcohol-related liver disease, or a
serum alcohol level ≥ 80 mg/dl), cirrhosis (ICD-9 code for
cirrhosis), end stage renal disease (ICD-9 code for end-
stage renal disease or procedure code for hemodialysis),
psychiatric disease [27, 28] (ICD-9 code for affective
disorder, anxiety disorder, schizophrenia, or psychosis),
and ALT elevation (using the highest ALT value re-
ported, considered elevated if > 40 U/L) [29, 30]. In
addition, we examined a composite variable, any risk-
associated factor, which included history of any of the
aforementioned variables, substance abuse, HIV infec-
tion, sexually transmitted infection, alcohol abuse, cir-
rhosis, end stage renal disease, history of psychiatric
illness, or ALT > 40 U/L. Each diagnosis was repre-
sented by a group of ICD-9 codes using the classifica-
tion system of the Healthcare Cost and Utilization
Project of the Agency for Healthcare Research and Quality
system [31] (Appendix: Table 2).
Statistical analysis
To determine if patients identified as HCV Ab + during
the pre-intervention vs. post intervention phases had dif-
ferent risk profiles, we compared demographic and HCV
risk characteristics between the two groups using t-tests,
Chi-squared and Fisher’s exact tests, as appropriate. A
p-value < 0.05 was considered significant.
STATA/IC software, version 10.0, (StataCorp, College
Station, TX) was used for all data management and statis-
tical analysis. The Institutional Review Boards of Boston
University Medical Center and Montefiore Medical
Center approved this study.
Results
The study sample included 164 patients who were newly
identified HCV Ab+. The study population mean age
was 49.9 +/− 12.0 years, 57.9 % male, 60.4 % Latino,
26.2 % non-Hispanic Black and 4.9 % non-Hispanic
White. Of these, 105 patients (64.0 %) were identified
HCV Ab + during the risk-based phase and 59 patients
(36.0 %) during the birth-cohort phase. Patients identi-
fied during the birth-cohort phase were less likely to be
male (49.1 % vs. 62.9 %, p = 0.09), but the difference was
not significant. The patient groups were similar with re-
spect to age and racial/ethnic characteristics.
Compared to the risk-based phase, patients identified
during the birth-cohort phase were significantly less
likely to have a documented history of substance abuse
(30.5 % vs. 49.5 %, p = 0.02), an ALT measurement > 40
U/L (22.0 % vs. 46.7 %, p = 0.002), or the composite any
risk-associated factor (55.9 % vs. 79.0 %, p = 0.002). In
addition, other co-morbidities were less common in the
birth-cohort group, including HIV infection (10.2 % vs.
19.0 %, p = 0.13), cirrhosis (0.0 % vs. 4.7 %, p = 0.16), and
history of psychiatric illness (11.9 % vs. 21.9 %, p = 0.11),
but the differences were not significant (Table 1).
Discussion
We found that patients who were newly identified as
HCV Ab + after a birth-cohort testing intervention were
significantly less likely to have a documented indication
for HCV testing than patients identified during the risk-
based testing phase. Specifically, birth-cohort phase pa-
tients were significantly less likely to have a documented
history of substance abuse or elevated serum ALT levels.
In addition, it was less common for birth-cohort phase
patients to have one of several diagnoses that might trig-
ger and HCV test including of HIV infection, cirrhosis,
or a history of psychiatric illness. Our study highlights
an important limitation of a risk-based testing strategy
and suggests that providers using a birth-cohort testing
strategy may find HCV infection among a number of
Fig. 1 The birth-cohort reminder sticker placed in the chart during the birth-cohort testing phase of the study
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patients without an identified risk or clinical indication
for testing whose infection would not have been found
otherwise.
Though risk-based testing is important given the high
prevalence of disease among patients with known risk
factors, this testing strategy has had limited effectiveness.
The majority of the HCV-infected individuals in the
United States are still unaware of their infection 25 years
after the discovery of the hepatitis C virus [14, 15]. Risk-
based testing is limited because it is dependent on the
physician’s willingness and time to inquire about risk, as
well as a patient’s ability to recall risk exposure, such as
a blood transfusion prior to 1992, or comfort with dis-
closing risk, such as injection drug use (IDU) [32]. As a
result, risk-based testing may not identify HCV-infected
patients despite exposure to risk at some point in their
lives. It is likely that most of the patients in the study
were exposed to HCV through injection drug use [9].
However, during the birth-cohort intervention phase the
vast majority of patients (41 of 59) did not have sub-
stance abuse as an identified risk in their medical chart,
highlighting the limitations of risk-based testing. A
birth-cohort only testing strategy also has limitations: it
would fail to identify infection among young people who
inject drugs, a critical group in the ongoing spread of
HCV infection. For this reason it is likely that a combin-
ation of risk-based and birth-cohort testing is optimal in
the US.
In addition, elevated ALT levels may be a common
reason for testing a patient for HCV, but many patients
with HCV infection do not have elevated liver enzymes
and their infection may be missed [33, 34]. Our results
suggest that the birth-cohort testing strategy is more
likely to identify HCV- Ab + individuals without an ele-
vated ALT level. This study demonstrated that individ-
uals living with HCV who do not have known HCV
risks may be identified through birth-cohort testing.
These individuals will now be able to receive confirma-
tory testing, and if appropriate, proper counseling, care,
and treatment for their infection.
Now more than ever, identification of all HCV-positive
individuals is crucial. With the advent of highly effective,
tolerable and easily administered HCV medications, we
have an opportunity to halt rising morbidity and mortality,
and there is long-term potential for eradication of HCV
disease [35]. Effective testing remains the first step in this
Table 1 Characteristics of Patients Identified HCV Positive using Risk-based vs. Birth-cohort Strategies
Risk-based phase Birth-cohort phase
n = 105 (%) n = 59 (%) p value
Age 50.5 ± 10.8 48.9 ± 12.0 0.45
Male 66 (62.9) 29 (49.2) 0.09
Race/Ethnicity 0.99
White 5 (4.8) 3 (5.1) 0.99
Black 27 (25.7) 16 (27.1) 0.84
Hispanic 64 (61.0) 35 (59.3) 0.84
Other/Unknown 9 (8.6) 5 (8.5) 0.98
Insurance 0.66
Medicare 5 (4.8) 5 (8.5) 0.34
Medicaid 83 (79.0) 42 (71.2) 0.26
Commercial 8 (7.6) 5 (8.5) 0.85
Self 9 (8.6) 7 (11.9) 0.49
History Substance Abuse 52 (49.5) 18 (30.5) 0.02
HIV Infection 20 (19.0) 6 (10.2) 0.13
History STIa 2 (1.9) 0 (0.0) 0.54
Alcohol Abuse 4 (3.8) 1 (1.7) 0.65
Cirrhosis 5 (4.7) 0 (0.0) 0.16
End Stage Renal Disease 0 (0.0) 2 (3.4) 0.13
History Psychiatric Illness 23 (21.9) 7 (11.9) 0.11
ALT > 40 U/L 49 (46.7) 13 (22.0) 0.002
Any Factorb 83 (79.0) 33 (55.9) 0.002
aSTI: Sexually Transmitted Infection
bAny Factor: History Substance Abuse, HIV Infection, Sexually Transmitted Infection, Alcohol Abuse, Cirrhosis, End Stage Renal Disease, History of Psychiatric illness,
or ALT > 40 U/L
Southern et al. BMC Infectious Diseases  (2015) 15:553 Page 4 of 7
process. As shown in this study, birth-cohort testing
may help identify those without known risk factors, im-
proving the detection rates and treatment opportunity
for a subset of those currently unaware of their infec-
tion. Studies have shown that birth-cohort screening is
cost-effective, even in the era of expensive direct-acting
antivirals [36], and models have predicted that implemen-
tation of this screening strategy could avert 78,000-
121,000 deaths, and over 10,000–19,000 liver transplants
among those living with HCV who remain undiagnosed
[36, 37].
Our study has several limitations. First, the CDC and
USPSTF birth-cohort testing guidelines were developed
based on HCV prevalences in the U.S and may not be
applicable outside the U.S. Whether there are birth-
cohort populations outside of the U.S. that would bene-
fit from testing is unknown. Next, we measured HCV
antibody positivity, not RNA confirmed HCV infection.
In addition, our risk-associated factors were primarily de-
fined by ICD-9 codes which may have resulted in mis-
classification. Although we believe that this classification
is likely non-differential and did not bias our results, we
cannot confirm that this is so. Next, we did not measure
the adherence to the intervention or the durability of the
intervention. In addition, we were not able to directly
measure risks for HCV infection (e.g., injection drug use)
and so instead measured surrogates for risk that, if noted,
might provoke HCV testing. Finally, because our sample
size was relatively small we were unable to perform multi-
variate analyses.
Conclusions
The majority of HCV-infected persons remain unidenti-
fied. Now that curative therapy is available, uptake of
Centers for Disease Control and Prevention and US
Preventive Services Task Force HCV screening guidelines
for birth cohort testing is critical so that HCV-infected in-
dividuals with no known risk factors or apparent clinical
indications for testing can be identified.
Appendix
Table 2 ICD-9 Code Diagnosis Grouping
Diagnosis grouping ICD-9 Codes
Substance Abuse 304.0 ,304.00,304.01, 304.02, 304.03, 304.1, 304.10, 304.11, 304.12, 304.13, 304.2, 304.20, 304.21, 304.22, 304.23, 304.3, 304.30,
304.31, 304.32, 304.33, 304.4, 304.40, 304.41, 304.42, 304.43, 304.5, 304.50, 304.51, 304.52, 304.53, 304.6, 304.60, 304.61, 304.62,
304.63, 304.7, 304.70, 304.71, 304.72, 304.73, 304.8, 304.80, 304.81, 304.82, 304.83, 304.9, 304.90, 304.91, 304.92, 304.93, 305.2,
305.20, 305.21, 305.22, 305.23, 305.3, 305.30, 305.31, 305.32, 305.33, 305.4, 305.40, 305.41, 305.42, 305.43, 305.5, 305.50, 305.51,
305.52, 305.53, 305.6, 305.60, 305.61, 305.62, 305.63, 305.7, 305.70, 305.71, 305.72, 305.73, 305.8, 305.80, 305.81, 305.82, 305.83,
305.9, 305.90, 305.91, 305.92, 305.93, 292.0, 292.1, 292.11, 292.12, 292.2, 292.8, 292.81, 292.82, 292.83, 292.84, 292.85, 292.89,
292.9, 648.3
HIV 042, 042.0, 042.1, 042.2, 042.9, 043.0, 043.1, 043.2, 043.3, 043.9, 044.0, 044.9, 079.53, 279.10, 279.19, 795.71, 795.8, V08
Sexually Transmitted
Infection
090.0, 090.1, 090.2, 090.3, 090.40, 090.41, 090.42, 090.49, 090.5, 090.6, 090.7, 090.9, 091.0, 091.1, 091.2, 091.3, 091.4, 091.50,
091.51, 091.52, 091.61, 091.62, 091.69, 091.7, 091.81, 091.82, 091.89, 091.9, 092.0, 092.9, 093.0, 093.1, 093.20, 093.21, 093.22,
093.23, 093.24, 093.81, 093.82, 093.89, 093.9, 094.0, 094.1, 094.2, 094.3, 094.81, 094.82, 094.83, 094.84, 094.85, 094.86, 094.87,
094.89, 094.9, 095.0, 095.1, 095.2, 095.3, 095.4, 095.5, 095.6, 095.7, 095.8, 095.9, 096, 097.0, 097.1, 097.9, 098.0, 098.10, 098.11,
098.12, 098.13, 098.14, 098.15, 098.16, 098.17, 098.19, 098.2, 098.30, 098.31, 098.32, 098.33, 098.34, 098.35,
098.36, 098.37, 098.39,
098.40, 098.41, 098.42, 098.43, 098.49, 098.50, 098.51, 098.52, 098.53, 098.59, 098.6, 098.7, 098.81, 098.82, 098.83, 098.84, 098.85,
098.86, 098.89, 099.0, 099.1, 099.2, 099.3, 099.4, 099.40, 099.41, 099.49, 099.50, 099.51, 099.52, 099.53, 099.54, 099.55, 099.56,
099.59, 099.8, 099.9
Alcohol Abuse 291.81, 305.0, 303.0, 303.9, 655.4, 760.71, 291.1, 291.89, 291.2, 425.5, 291.0, 291.1, 291.2, 291.3, 291.82, 291.9, 291.5, 291.9, 291.4,
571.0, 571.3, 571.1, 571.2, 265.2, 980.9, 303.90, 303.91, 303.92, 303.93, 648.4, 760.71, V11.3




Psychiatric Diagnosis 295.00, 295.01, 295.02, 295.03, 295.04, 295.05, 295.10, 295.11, 295.12, 295.13, 295.14, 295.15, 295.20, 295.21, 295.22, 295.23,
295.24, 295.25, 295.30, 295.31, 295.32, 295.33, 295.34, 295.35, 295.40, 295.41, 295.42, 295.43, 295.44, 295.45, 295.50, 295.51,
295.52, 295.53, 295.54, 295.55, 295.60, 295.61, 295.62, 295.63, 295.64, 295.65, 295.70, 295.71, 295.72, 295.73, 295.74, 295.75,
295.80, 295.81, 295.82, 295.83, 295.84, 295.85, 295.90, 295.91, 295.92, 295.93, 295.94, 295.95, 296.00, 296.01, 296.02, 296.03,
296.04, 296.05, 296.06, 296.10, 296.11, 296.12, 296.13, 296.14, 296.15, 296.16, 296.20, 296.21, 296.22, 296.23, 296.24, 296.25,
296.26, 296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.40, 296.41, 296.42, 296.43, 296.44, 296.45, 296.46, 296.50,
296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.7, 296.80, 296.81,
296.82, 296.89, 296.90, 296.99, 297.0, 297.1, 297.2, 297.3, 297.8, 297.9, 298.1, 298.2, 298.3, 298.4, 298.8, 298.9, 298.0, 300.4,
301.11, 301.13, 299.00, 299.01, 299.10, 299.11, 299.80, 299.81, 299.90, 299.91, 300.00, 300.01, 300.02, 300.09, 300.10, 300.11,
300.12, 300.13, 300.14, 300.15, 300.16, 300.19, 300.20, 300.21, 300.22, 300.23, 300.29, 300.3, 300.5, 300.6, 300.7, 300.81,
300.82, 301.0, 301.10, 301.12, 301.20, 301.21, 301.22, 301.3, 301.4, 301.50, 301.51, 301.59, 301.6, 301.7, 301.81, 301.82,
301.83, 301.84, 301.89, 301.9, 307.40, 307.41, 307.42, 307.43, 307.44, 307.45, 307.47, 307.48, 307.49, 307.80, 307.81, 307.89,
307.9, 308.0, 308.1, 308.2, 308.3, 308.4, 308.9, 309.81, 312.30, 312.31, 312.32, 312.33, 312.34, 312.35, 312.39
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